Internal Reference Number: FOI_9691
Date Request Received: 07/10/2026 00:00:00
Date Request Replied To: 27/10/2026 00:00:00
This response was sent via: By Email
Request Summary: Lung Cancer
Request Category: Researcher
| Question Number 1: How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) • Amivantamab Monotherapy • Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) • Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel • Atezolizumab monotherapy (subcutaneous injection only) • Dabrafenib + Trametinib • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin • Durvalumab • Gemcitabine • Nintedanib + Docetaxel • Nivolumab • Osimertinib • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) • Paclitaxel • Pembrolizumab Monotherapy • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) • Pemetrexed + Platinum (Carboplatin/Cisplatin) • RET Inhibitors (Pralsetinib, Selpercatinib) • Sotorasib • Tepotinib • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin • Other active systemic anti-cancer therapy • Palliative care only • Amivantamab with carboplatin and pemetrexed • Cemiplimab with platinum-based chemotherapy • Adagrasib • Datopotamab deruxtecan • Amivantamab with lazertinib • Pembrolizumab subcutaneous injection | |
| Answer To Question 1: How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) - 8 • Amivantamab Monotherapy - 0 • Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) - 7 • Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel - 0 • Atezolizumab monotherapy (subcutaneous injection only) - 6 • Dabrafenib + Trametinib less than 5 • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin - 0 • Durvalumab less than 5 • Gemcitabine - 0 • Nintedanib + Docetaxel less than 5 • Nivolumab - 0 • Osimertinib - 10 • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) - 0 • Paclitaxel - 0 • Pembrolizumab Monotherapy less than 5 • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) - 11 • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) - 7 • Pemetrexed + Platinum (Carboplatin/Cisplatin) less than 5 • RET Inhibitors (Pralsetinib, Selpercatinib) - 0 • Sotorasib less than 5 • Tepotinib less than 5 • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin - 0 • Other active systemic anti-cancer therapy - 0 • Palliative care only - 14 • Amivantamab with carboplatin and pemetrexed - 0 • Cemiplimab with platinum-based chemotherapy - 0 • Adagrasib - 0 • Datopotamab deruxtecan - 0 • Amivantamab with Lazertinib - 0 • Pembrolizumab subcutaneous injection - 12 | |
| To return to the list of all the FOI requests please click here |
Our staff at Â鶹¹ú²ú District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
